In the IMvigor210 trial, TMB assessed by targeted genomic profiling of 315 cancer-related genes (Foundation Medicine) correlated with a longer OS and ORR with atezolizumab independent of PD-L1 expression. This evidence concerns the gene CD274 and cancer.